Neil Kumar - Mar 12, 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
CEO and President, Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Mar 12, 2024
Transactions value $
$0
Form type
4
Date filed
3/14/2024, 04:00 PM
Previous filing
Feb 21, 2024
Next filing
May 17, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (right to buy) Award $0 +45.1K $0.00 45.1K Mar 12, 2024 Common Stock 45.1K $28.70 Direct F1
transaction BBIO Restricted Stock Units Award $0 +314K $0.00 314K Mar 12, 2024 Common Stock 314K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/16th of the shares subject to this option vest and become excercsiable on May 16, 2024, and thereafter, 1/16th of the shares subject to this option will vest and become exercisable on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2024, and thereafter, 1/16th of the underlying shares will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.